QRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHR

Key Points

• QRG Capital Management Inc. increased its stake in United Therapeutics Corporation by 6.2%, bringing its total holdings to 17,770 shares worth approximately $5.1 million.
• Several institutional investors have significantly adjusted their positions in United Therapeutics, with Allianz Asset Management increasing its holdings by 96.9% and now owning 67,576 shares valued at about $20.8 million.
• United Therapeutics recently reported earnings of $6.41 per share, falling short of analyst estimates, and had a 12-month stock price range between $266.98 and $455.12.

QRG Capital Management Inc. boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 6.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 17,770 shares of the biotechnology company's stock after buying an additional 1,045 shares during the period. QRG Capital Management Inc.'s holdings in United Therapeutics were worth $5,106,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. XTX Topco Ltd bought a new position in shares of United Therapeutics in the 1st quarter valued at about $313,000. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after acquiring an additional 33,254 shares during the period. LPL Financial LLC increased its holdings in United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after buying an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after buying an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new position in United Therapeutics during the first quarter valued at approximately $227,000. Institutional investors own 94.08% of the company's stock.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Insiders sold a total of 238,435 shares of company stock worth $93,353,482 over the last quarter. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 2.2%

Shares of NASDAQ UTHR opened at $453.07 on Monday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $455.12. The stock has a market cap of $20.44 billion, a PE ratio of 17.68, a P/E/G ratio of 6.91 and a beta of 0.66. The company has a 50-day moving average of $356.31 and a 200 day moving average of $319.05.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same period in the prior year, the company posted $5.85 EPS. The firm's revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on UTHR shares. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. Morgan Stanley lowered their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Finally, Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Ten research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.